Nine-Month Figures for 2018

Sartorius Stedim Biotech Continues to Grow by Double Digits - Seite 2

The Group's key financial indicators remained at very robust levels. At the end of the reporting period, the ratio of net debt to underlying EBITDA stood at 0.4, and company's equity ratio was 61.6% (Dec. 31, 2017: 0.4 and 62.6%, resp.). The CAPEX ratio in the first nine months of 2018 was 13.9%, in-line with expectations (9M 2017: 11.3%). Investment activities focused on the expansion of the plant for manufacturing single-use bags and filters in Puerto Rico, IT and digitalization projects, and on the consolidation and expansion of sites and production capacity levels in Göttingen, Germany.

2018 guidance confirmed and specified

In view of positive business development in the first nine months of 2018, management specified its full-year guidance as follows: Sales revenue growth is now projected to be in the upper range of the previously targeted bandwidth of 11% to 14% while the underlying EBITDA margin continues to be expected at around 28.0%, up from the prior-year figure of 27.3.

All forecasts are based on constant currencies. As a result of changes in the currency exchange rates, reported figures in actual currencies may differ from constant currency guidance.

¹⁾ Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items) as the key profitability indicator

²⁾ EMEA = Europe | Middle East | Africa

³⁾ After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference call

Joachim Kreuzburg, Chairman of the Board and CEO of the Sartorius Stedim Biotech Group, will discuss the company’s results with analysts and investors on Tuesday, October 23, 2018, at 3:00 p.m. Central European Time (CEST), in a teleconference. You may register for the teleconference at:

http://services.choruscall.de/DiamondPassRegistration/register?confirm ...

Alternatively, you can dial into the teleconference, without registering, at:

[phone]

To view the presentation, log onto: https://www.sartorius.com/en/company/investor-relations/sartorius-sted ...